Global Kidney Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Global Kidney Cancer Diagnostics Market - Industry Trends and Forecast to 2030

Global Kidney Cancer Diagnostics Market, By Test Type (Imaging, Biomarker Test, Blood Test, Biopsy, Genetic Test, and Others), Cancer Stages (Stage I , Stage II, Stage III and Stage IV), Tumor Type (Renal Cell Carcinoma, Clear cell renal cell carcinoma, non-clear cell renal cell carcinoma), Product (Platform-Based Products, Instrument based products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender,Retail Sales and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland and the rest of Europe, China, Japan, India, Australia, New Zealand, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Taiwan and the rest of Asia-Pacific, South Africa, Saudi Arabia, Bahrain, UAE, Kuwait, Oman, Qatar, Egypt, Israel and the Rest of Middle East and Africa, Brazil, Argentina, and the Rest of South America), Industry Trends and Forecast to 2030.

Market Definition

Kidney cancer, commonly known as renal cancer, is a condition in which kidney cells develop into malignant (cancerous) tumors and expand uncontrollably. One of the top 10 most prevalent cancers is kidney cancer. Kidney cancer is fatal, and the diagnosis process also has safety issues; it is not cost-effective. One of the most costly medical disorders to treat globally is cancer. Cancer patients may be hospitalized and receive a variety of therapies, such as surgery, radiation therapy, and systemic therapy. About 40% of kidney growths are tiny, localized masses. Localized refers to a tumor that has not spread from its original location. Kidney masses cannot be detected with regular laboratory procedures. Diagnosis of kidney cancer includes biopsy procedures, blood tests, and Imaging tests. Advanced kidney cancer therapies, like immunotherapy, radiation therapy, etc., are advised. Due to cutting-edge methods, nonsurgical procedures like cryoablation (which freezes cancer cells) and radiofrequency ablation are sometimes used to treat minor kidney tumors (heat cancer cells).

Kidney cancer can be difficult to diagnose because, despite its wide range of signs and symptoms, they are non-specific and can be linked to other, more widespread medical conditions. More than 43,000 men and 25,000 women are diagnosed with kidney and renal pelvis cancer each year, and 9,000 men and 5,000 women pass away as a result of this illness. However, strict regulations and standards for the approval and commercialization of kidney cancer diagnostic products are expected to restrain market growth.

Market Segmentation

The global kidney cancer diagnostics market is segmented into eight notable segments based on test type, cancer stages, tumor type, product, application, technology, end user and distribution channel.
• On the basis of test type, the global kidney cancer diagnostics market is segmented into imaging, biomarker test, blood test, biopsy, genetic test, and others
• On the basis of cancer stages, the global kidney cancer diagnostics market is segmented into stage I, stage II, stage III and stage IV
• On the basis of tumor type, the global kidney cancer diagnostics market is segmented into renal cell carcinoma, Clear cell renal cell carcinoma, and non-clear cell renal cell carcinoma.
• On the basis of product, the global kidney cancer diagnostics market is segmented into instrument-based products, platform-based products, kits and reagents, and other consumables
• On the basis of technology, the global kidney cancer diagnostics market is segmented into fluorescent in situ hybridization, next generation sequencing, fluorimmunoassay, comparative genomic hybridization, immunohistochemical, and others
• On the basis of application, the global kidney cancer diagnostics market is segmented into screening, diagnostic and predictive, prognostic, and research
• On the basis of end user, the global kidney cancer diagnostics market is segmented into hospitals, diagnostic centers, cancer research centers, academic institutes, ambulatory surgical centers, and others
• On the basis of distribution channel, the global kidney cancer diagnostics market is segmented into direct tender, retail sales and others

Market Players

Some of the major players operating in the global kidney cancer diagnostics market are:
• Ambry Genetics
• BD
• BioVendor R&D
• BluePrint Oy.
• Canon Medical Systems Corporation
• CD Genomics
• CENTOGENE N.V.
• Creative Diagnostics
• FUJIFILM Corporation
• GeneDx,LLC
• GenPath
• Grail
• Illumina, Inc.
• Invitae Corporation
• Koninklijke Philips N.V.
• Laboratory Corporation of America Holdings
• Myriad Genetics,Inc.,
• Qiagen
• Seimens Healthcare GmbH
• Thermo Fisher Scientific Inc.